Skip to main content

Table 1 Features of patients receiving SOC or CCP

From: Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden

 

SOC (n = 14)

CCP (n = 17)

Demographics

 Age (years)a

65 (43–84)

80 (60–86)

 Sex (male)b

8 (57)

11 (65)

 BMI (kg/m2)a

31 (26–35)

28 (24–34)

 Charlson comorbidity indexa

1 (0–2)

1 (0–2)

 Arterial hypertensionb

6 (42)

7 (41)

Factors at inclusion

 Symptom duration (days)a

8 (5–11)

7 (5–9)

 CRP (mg/L)a

100 (58–133)

72 (40–120)

 Lymphocyte count (109/L)a

0.8 (0.5–1.4)

0.9 (0.5–1.4)

 Oxygen (L/min)a

2.5 (1–5)

2 (1.5–3)

 Patients with SARS-CoV-2 antibodies at inclusiona,c

2 (18%)

1 (8%)

Treatment

 Betametasonb

11 (79)

11 (65)

 Remdesivirb

1 (7)

2 (12)

 Intravenous antibioticsb

7 (50)

8 (53)

 Anti-coagulantsb

14 (100)

14 (82)

  1. aMedian (IQR). bNumbers (%). cData available for 11 SOC-patients and 13 CCP-patients